Novartis Financial Statements From 2010 to 2024

NVSEF Stock  USD 95.68  0.71  0.74%   
Novartis financial statements provide useful quarterly and yearly information to potential Novartis AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Novartis financial statements helps investors assess Novartis' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Novartis' valuation are summarized below:
Novartis AG does not presently have any fundamental ratios for analysis.
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
This module can also supplement various Novartis Technical models . Check out the analysis of Novartis Correlation against competitors.

Novartis Number Of Employees Analysis

Novartis' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Number of Employees

 = 

Full Time

+

Part Time

More About Number Of Employees | All Equity Analysis

Current Novartis Number Of Employees

    
  102 K  
Most of Novartis' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Competition

Based on the recorded statements, Novartis AG is currently employing 102 K people. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The number of employees for all United States stocks is much lower than that of the firm.

Novartis AG Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.
Novartis AG is considered to be number one stock in net income category among related companies. It is rated top company in revenue category among related companies totaling about  7.45  of Revenue per Net Income. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novartis by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novartis' Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.

About Novartis Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 104323 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out the analysis of Novartis Correlation against competitors.
Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Novartis Pink Sheet analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.